Differentiated Thyroid Cancer: I-131 Therapy

Quick Answer

I-131 therapy for differentiated thyroid cancer (DTC) exploits the tumor's retained sodium-iodide-symporter trapping to deliver targeted beta radiation, in a risk-adapted framework: remnant ablation (destroy residual normal thyroid to simplify surveillance), adjuvant therapy (treat suspected microscopic disease), or treatment of known iodine-avid residual/metastatic disease. Activity scales with ATA risk: ~30 mCi (1.1 GBq) for low-risk ablation up to ~100–200 mCi for higher-risk/known disease (or dosimetry-guided for advanced cases). Success requires TSH stimulation (thyroid-hormone withdrawal or rhTSH) and a low-iodine diet, and every therapy is followed by a post-therapy whole-body scan — the most sensitive functional map of disease.

Background & Rationale

DTC (papillary and follicular) usually retains iodine avidity, so after total thyroidectomy I-131 can ablate remnant thyroid and treat iodine-avid disease — while enabling thyroglobulin (Tg) and whole-body-scan surveillance. Not all patients need RAI: risk stratification (ATA low/intermediate/high) decides whether and how much to give. (Contrast medullary and anaplastic cancers, which lack the symporter — no RAI role.)

The Three Goals (and typical activities)

Risk-adapted evidence: the ESTIMABL and HiLo trials showed low-activity (30 mCi) ablation with rhTSH is non-inferior to 100 mCi with withdrawal for low-risk ablation — supporting the lowest effective activity. High-risk and distant disease favor higher activities or lesional/blood-based dosimetry (Benua limits: ≤ ~2 Gy blood, ≤ ~120 mCi whole-body retention at 48 h, ≤ ~80 mCi with diffuse lung mets to avoid pneumonitis/fibrosis).

Patient Preparation

• TSH stimulation to drive symporter expression: thyroid-hormone withdrawal (stop levothyroxine ~3–4 weeks, ± T3 bridge, to TSH > 30 mU/L) or recombinant human TSH (rhTSH / Thyrogen) injections (avoids hypothyroid symptoms; standard for low/intermediate-risk ablation).
• Low-iodine diet for 1–2 weeks (deplete the stable-iodine pool so tumor avidly traps I-131); avoid iodinated CT contrast for ~6–8 weeks and screen for amiodarone.
• Exclude pregnancy; counsel on radiation-safety/patient-release and avoiding conception (~6–12 months).

Post-Therapy Whole-Body Scan

A post-therapy scan at ~5–8 days (using the therapeutic I-131's 364-keV gamma, ± SPECT/CT) is more sensitive than any diagnostic scan for functioning disease because of the high administered activity — it frequently upstages disease and guides follow-up. Correlate with stimulated Tg.

Interpretation & Surveillance

• Thyroglobulin (Tg) is the key tumor marker (only meaningful after thyroidectomy ± ablation); anti-Tg antibodies invalidate Tg and are a caveat.
• Rising Tg with a negative diagnostic RAI scan (Tg-positive/scan-negative) suggests dedifferentiated / RAI-refractory disease → image with FDG-PET (the "flip-flop": iodine-avid = FDG-low, dedifferentiated = FDG-avid).
• Functioning metastases on the post-therapy scan define iodine-avid disease amenable to further I-131.

RAI-Refractory Disease

When disease no longer concentrates iodine (or progresses despite RAI), further I-131 is futile. Options: FDG-PET for restaging, multikinase inhibitors (lenvatinib, sorafenib), selective inhibitors for driver mutations (BRAF/NTRK/RET), and redifferentiation strategies (MEK/BRAF inhibitors to restore iodine uptake before re-attempting RAI).

Toxicity & Safety

• Sialadenitis/xerostomia (salivary NIS uptake), transient neck pain/swelling, taste changes, nausea.
• Bone-marrow suppression (transient) at higher/repeated activities; pulmonary fibrosis risk with diffuse lung mets (dose-limit).
• Secondary-malignancy and fertility considerations with high cumulative activity.
• I-131's penetrating 364-keV gamma drives patient-release rules (see radiation-safety page); higher activities may require inpatient management by jurisdiction.

Common Pitfalls

• Stunning: a diagnostic I-131 activity can transiently reduce subsequent therapeutic uptake — prefer I-123 (or low diagnostic activity / proceed empirically) for pre-therapy scans.
• Iodine contamination (recent contrast, amiodarone, non-compliant diet) blunting uptake.
• Inadequate TSH stimulation (insufficient withdrawal or missed rhTSH) reducing efficacy.
• Treating RAI-refractory or non-iodine-avid (MTC/anaplastic) disease with I-131.

Board Pearls

DTC I-131 therapy is risk-adapted: remnant ablation (~30 mCi, low-risk), adjuvant (~75–150 mCi), or treatment of iodine-avid disease (~100–200 mCi / dosimetry). ESTIMABL/HiLo established 30 mCi + rhTSH non-inferior to 100 mCi + withdrawal for low-risk ablation. Every therapy needs TSH stimulation (withdrawal to TSH >30 or rhTSH) and a low-iodine diet, and is followed by a post-therapy whole-body scan — the most sensitive disease map.

Stunning: a diagnostic I-131 activity can reduce therapeutic uptake — use I-123 or proceed empirically. Screen for the iodine-load trap (contrast, amiodarone, diet). Tg-positive / diagnostic-scan-negative disease is dedifferentiated/RAI-refractory → image with FDG-PET (iodine-avid = FDG-low; dedifferentiated = FDG-avid — the flip-flop).

Dosimetric ceilings (Benua): ≤ ~2 Gy blood, ≤ ~120 mCi 48-h whole-body retention, ≤ ~80 mCi with diffuse lung metastases (pneumonitis/fibrosis risk). RAI-refractory disease → lenvatinib/sorafenib, driver-targeted (BRAF/RET/NTRK) agents, and redifferentiation (MEK/BRAF) to restore iodine avidity. MTC and anaplastic cancers lack the symporter — no RAI role.

Related Pages

• Tracer: Radioiodine (I-123/I-131); diseases: Thyroid cancer, ATA risk stratification; safety: Radiation safety & patient release.

Figure / Diagram Suggestions

• A risk-adapted activity ladder (ablation → adjuvant → treatment).
• A withdrawal vs rhTSH prep comparison timeline with low-iodine diet.
• The iodine-avid ↔ FDG-avid "flip-flop" schematic for RAI-refractory disease.

Self-Check